BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
PFA re-energizes afib market
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, September 1, 2024
See today's BioWorld
Home
» Simcere gets China rights for Idorsia’s daridorexant in $50M deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Simcere gets China rights for Idorsia’s daridorexant in $50M deal
Nov. 17, 2022
By
David Ho
No Comments
Simcere Pharmaceutical Group Ltd. has inked a licensing agreement picking rights to develop Idorsia Ltd.’s insomnia treatment in greater China, in exchange for a $30 million up-front payment.
BioWorld
Deals and M&A
Neurology/psychiatric
China